Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

920 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Zhang B, Cheng Z, Chen J, Zhang X, Liu D, Jiang H, Ma G, Wang X, Gan S, Sun J, Jin P, Yi J, Shi B, Ma J, Ye S, Wang G, Ji L, Gu X, Yu T, An P, Deng H, Li H, Li L, Ma Q, Qian L, Yang W. Zhang B, et al. Among authors: an p. Diabetes Care. 2024 Jan 1;47(1):160-168. doi: 10.2337/dc23-1287. Diabetes Care. 2024. PMID: 37943529 Free PMC article. Clinical Trial.
Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).
Chai M, He Y, Zhao W, Han X, Zhao G, Ma X, Qiao P, Shi D, Liu Y, Han W, An P, Li H, Yan S, Ma Q, Deng H, Qian L, Zhou Y; CREDIT-2 investigators. Chai M, et al. Among authors: an p. BMC Med. 2023 Feb 28;21(1):77. doi: 10.1186/s12916-023-02797-8. BMC Med. 2023. PMID: 36855099 Free PMC article. Clinical Trial.
Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial.
Qi L, Liu D, Qu Y, Chen B, Meng H, Zhu L, Li L, Wang S, Liu C, Zheng G, Lian Q, Yin G, Lv L, Lu D, Chen X, Xue F, An P, Li H, Deng H, Li L, Qian L, Huo Y. Qi L, et al. Among authors: an p. JACC Asia. 2023 Jul 11;3(4):636-645. doi: 10.1016/j.jacasi.2023.04.011. eCollection 2023 Aug. JACC Asia. 2023. PMID: 37614541 Free PMC article.
Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial.
Huo Y, Chen B, Lian Q, Wang S, Liu L, Lu D, Qu Y, Zheng G, Li L, Ji Y, Yin G, Huang W, Xie Y, Yang X, Gao X, An P, Xue F, Li H, Deng H, Li L, Pei L, Qian L. Huo Y, et al. Among authors: an p. Lancet Reg Health West Pac. 2023 Sep 28;41:100907. doi: 10.1016/j.lanwpc.2023.100907. eCollection 2023 Dec. Lancet Reg Health West Pac. 2023. PMID: 37808342 Free PMC article.
P53 upregulation by USP7-engaging molecular glues.
Li Z, Wang Z, Zhong C, Zhang H, Liu R, An P, Ma Z, Lu J, Pan C, Zhang Z, Cao Z, Hu J, Xing D, Fei Y, Ding Y, Lu B. Li Z, et al. Among authors: an p. Sci Bull (Beijing). 2024 Apr 11:S2095-9273(24)00251-2. doi: 10.1016/j.scib.2024.04.017. Online ahead of print. Sci Bull (Beijing). 2024. PMID: 38734583
Real-world evidence of combined treatment of biologics and exclusive enteral nutrition in patients with ileum-dominant Crohn's disease: A multicenter study.
Wang W, Yin A, Wang J, Li J, Cheng J, Kang J, Xu Y, Lu Y, Yang Y, Su J, Zhou Q, Liu Y, Tang Z, Ren H, Li W, Dong W, Yu B, An P. Wang W, et al. Among authors: an p. Clin Nutr. 2024 Apr 15;43(6):1291-1298. doi: 10.1016/j.clnu.2024.04.013. Online ahead of print. Clin Nutr. 2024. PMID: 38663050 Free article.
920 results